SCHEMBL8571925

SCHEMBL8571925

Cc1ccc2c(ccc3nc(C)ccc32)n1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
CYP1A2 P05177 4/20 0.52
LMNA P02545 2/20 0.48
POLB P06746 2/20 0.48
KDM4E B2RXH2 1/20 0.48
CASP6 P55212 1/20 0.48
CCR1 P32246 1/20 0.46
RAB9A P51151 1/20 0.46
CCR5 P51681 1/20 0.46
GPR3 P46089 1/20 0.42
KDM1A O60341 1/20 0.42
KMT2A Q03164 2/20 0.41
NCF1 P14598 1/20 0.41
OPRK1 P41145 1/20 0.41
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7512293 0.84 CYP1A2 (0.59) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL7058875 0.84 CYP1A2 (0.59) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL11287166 0.83 CCR1 (0.61) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL862762 0.83 ALDH1A1 (0.55) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL8573961 0.82 MAPT (0.64) ALDH1A1CYP1A2LMNAKDM4EKMT2A
SCHEMBL24608630 0.79 KDM4E (0.43) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL17532770 0.79 MAPK10 (0.47) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL17051644 0.79 CYP1A2 (0.46) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL7596225 0.79 ALDH1A1 (0.40) ALDH1A1CYP1A2LMNAPOLBKDM4E
SCHEMBL15296568 0.79 ALDH1A1 (0.51) ALDH1A1CYP1A2LMNAPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) 2013-04-04 US disclosed
US-5733785-A QUANTITATIVE ANALYSIS CHINERA RESEARCH CHEMICAL, INC. (US) 1998-03-31 US disclosed
EP-0806671-A1 Automated urinalysis system for detecting blood in urine Chimera Research and Chemical, Inc. (US) 1997-11-12 EP disclosed
US-4299917-A IMPREGNATION OF AN ABSORBENT CARRIER WITH A SULPHONPHTHALEIN ESTER AND AN ACTIVATOR BOEHRINGER MANNEHEIM GMBH (DE) 1981-11-10 US disclosed
EP-0014929-A1 Diagnostic means, process for its preparation and its use in determining leucocytes in body fluids Roche Diagnostics GmbH (DE) 1980-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT MAVS, SNRPE, LONP1 ALDH1A1 3082/4885CYP1A2 4452/4885LMNA 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.